By Eyal Avidov
Human plasma new Israeli Anti-Corona Passive Vaccine
Kamada slogan is: “Each life is unique”.
Following the outbreak of the global coronavirus crisis, Kamada initiated the development of an anti-Corona (SARS-COV-2) immunoglobulin (“Passive Vaccine”) using its proprietary plasma-derived IgG platform technology as a potential treatment for severely ill coronavirus patients. The product will be produced from plasma donated by patients recovering from COVID-19, which is expected to include antibodies to the Coronavirus (COVID19).
The rationale for the development of immunoglobulin (“Passive Vaccine”) is known and is based on treatment of an infectious disease with pathogen-specific antibodies. This concept has previously been shown to be effective in the treatment of severe acute viral infections, such as rabies, hepatitis, CMV and more says Amir London- KANADA’s CEO
Amir tolled us: Amir tolled us: Joining forces with Kedrion is expected to speed up the development of the product and strengthen Kamada’s international reach. The initial focus of the collaboration will be to provide the product as a treatment to patients in Italy, Israel, and the U.S. through various clinical programs, while subsequently expanding development and commercialization efforts to additional markets.
In light of the current global coronavirus outbreak, Kedrion and Kamada have quickly focused their efforts on developing and manufacturing a potentially safe and effective treatment, said Paolo Marcucci, Chief Executive Officer of Kedrion.
“We are excited to collaborate once again with Kamada, our partner for KEDRAB® [Rabies Immune Globulin (Human)]. Based on our collective expertise in plasma-derived protein therapeutics, we believe Kedrion and Kamada are uniquely positioned to develop, manufacture and supply, in a relatively short period of time, an Anti-SARS-CoV-2 IgG treatment. We believe we have an important opportunity to make a significant impact for patients in need during this pandemic.”
“As previously reported, we initiated the development of an Anti-SARS-CoV-2 polyclonal immunoglobulin and intend to begin clinical manufacturing of the product shortly. I believe that the collaboration with Kedrion, a global leader in plasma collection and plasma-derived therapeutics, will allow us to speed up the development of the product and strengthen our international reach,” said Amir London, Kamada’s Chief Executive Officer.
Our successful collaboration with Kedrion around our joint KEDRAB program is indicative of the unique capabilities of both companies, and we look forward to another successful partnership leveraging our strong working relationship and the core strengths of both companies.
Kamada Ltd (www.kamada.com), founded in 1990, is an Israeli-based publicly-traded (NASDAQ & TASE: KMDA) commercial stage plasma-derived biopharmaceutical company, with an existing marketed product portfolio and a late-stage product pipeline.
Amir London assumed responsibility as Kamada’s CEO in July 2015.
Prior to that, he has served as our Senior Vice President, Business Development. Mr. London brings with him over 20 years of senior management and international business development experience.
Prior to joining Kamada , Mr. London was the COO of Fidelis Diagnostics, a US-based provider of innovative in-office medical diagnostic services. Earlier in his career Mr. London was the CEO of Promedico, a leading Israeli-based $350 million healthcare distribution company, and the General Manager of Cure Medical, providing contract manufacturing services for clinical studies, as well as home-care solutions. Before that, for 10 years, Mr. London was a Partner with Tefen, an international publicly-traded operations management consulting firm, responsible for the firm’s global biopharma practice. Mr. London holds a B.Sc. in Industrial and Management Engineering from the Technion in Haifa, Israel.
Eyal Avidov-Lt. Col. (Ret.)
Contributing Writer and the Representative of News247WorldPress in Israel
BASTION HLS ® LTD
DEFENSE I VEHICLES I SOLUTIONS